Diabetes Diagnostics Market Report 2026

The diabetes diagnostics market size has grown strongly in recent years. It will grow from $27.31 billion in 2025 to $29.39 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising prevalence of diabetes, reliance on fingerstick blood glucose testing, growing hospital-based diagnostics, increasing awareness of glycemic control, expansion of diagnostic laboratories.

The diabetes diagnostics market size is expected to see strong growth in the next few years. It will grow to $38.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growth in continuous glucose monitoring usage, increasing adoption of homecare diagnostics, technological advancements in biosensors, rising healthcare expenditure, expansion of digital health ecosystems. Major trends in the forecast period include expansion of continuous glucose monitoring adoption, integration of smart and connected diagnostic devices, rising demand for home-based diabetes testing, increased focus on early diabetes screening programs, advancements in non-invasive glucose monitoring.

The higher prevalence of obesity is expected to drive the growth of the diabetes diagnostics market in the coming years. Obesity is defined as excessive accumulation of body fat that increases the risk of several health conditions, including heart disease and diabetes. The rising prevalence of obesity is linked to factors such as sedentary lifestyles, higher intake of processed and calorie-dense foods, genetic susceptibility, and reduced physical activity. Diabetes diagnostics aid in obesity management by enabling early identification of insulin resistance and abnormalities in glucose metabolism, allowing timely interventions to reduce weight-related health risks. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government authority, between 2023 and 2024, approximately 64.5% of adults aged 18 and above in England were overweight or living with obesity, up from 64% during 2022 to 2023. Therefore, the increasing prevalence of obesity is supporting the growth of the diabetes diagnostics market.

Major companies operating in the diabetes diagnostics market are prioritizing the development of innovative solutions, such as gestational diabetes diagnostic tools, to broaden their product offerings and address the rising demand for early detection and effective management of diabetes during pregnancy. Gestational diabetes diagnostic tools include medical devices and tests used to detect and monitor gestational diabetes in pregnant women, commonly involving blood glucose assessments such as the oral glucose tolerance test (OGTT) to evaluate how efficiently the body processes glucose during pregnancy. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, introduced the XpressGT RUO kit, an advanced biosensor designed to detect insulin resistance-related conditions including gestational diabetes, endometriosis, and liver disease. The kit delivers rapid results by measuring 2-hydroxybutyrate (2-HB) levels in venous blood and is compatible with standard clinical analyzers. This development aims to support earlier diagnosis and improve outcomes for a large patient population globally.

In September 2023, Abbott Laboratories Ltd., a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. Through this acquisition, Abbott Laboratories aims to strengthen its position in diabetes care, expand its FreeStyle Libre product portfolio, and accelerate the development of connected technologies that enable more personalized and precise diabetes management. Bigfoot Biomedical Inc. is a US-based medical technology company focused on innovative insulin management solutions.

Major companies operating in the diabetes diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Abbott Laboratories, Medtronic plc, DexCom Inc, Tandem Diabetes Care Inc, Ypsomed AG, LifeScan Inc, Nova Biomedical Corporation, Ascensia Diabetes Care Holdings AG, ARKRAY Inc, PTS Diagnostics Inc, AgaMatrix Inc, Senseonics Holdings Inc, DarioHealth Corp, Bionime Corporation, Acon Laboratories Inc, Sinocare Inc, i‑SENS Inc, Prodigy Diabetes Care LLC, Rossmax International Ltd, Menarini Diagnostics s.r.l, Trividia Health Inc, EKF Diagnostics Holdings plc.

North America was the largest region in the diabetes diagnostics market in 2025. The regions covered in the diabetes diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetes diagnostics market by increasing costs of imported glucose meters, continuous glucose monitoring sensors, diagnostic reagents, and electronic components. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported diagnostic devices, while Asia-Pacific faces higher costs for advanced monitoring systems. These tariffs are raising diagnostic testing costs. However, they are also encouraging local manufacturing of diagnostic devices, regional supply chain development, and improved availability of cost-effective diabetes testing solutions.

The diabetes diagnostics market research report is one of a series of new reports that provides diabetes diagnostics market statistics, including diabetes diagnostics industry global market size, regional shares, competitors with a diabetes diagnostics market share, detailed diabetes diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes diagnostics industry. This diabetes diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetes diagnostics refers to the techniques and tests used to detect and monitor diabetes by measuring blood glucose levels and other related biomarkers. It includes a range of medical evaluations designed to identify abnormal glucose metabolism and determine the risk or presence of diabetes. Accurate diagnostic methods support early detection, effective disease management, and informed treatment planning.

The primary product types in diabetes diagnostics include blood glucose meters, continuous glucose monitoring devices, lancets, test strips, and others. Blood glucose meters are portable medical devices that measure blood sugar levels by analyzing a small blood sample, typically obtained from a fingertip and applied to a test strip. These products are used for Type I diabetes, Type II diabetes, and gestational diabetes, and are utilized by various end users such as hospitals, diagnostic centers, home care settings, and others.

The diabetes diagnostics market consists of revenues earned by entities by providing services such as insulin sensitivity and resistance testing, neuropathy testing services, retinopathy screening services, and diabetes risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes diagnostics market also includes sales of glucose monitoring devices, HbA1c testing kits, and insulin pumps. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.